Differences between prognostic value of rs1625895 in male and female patients with diffuse large B-cell lymphoma
Author Affiliations1Novosibirsk State Medical University of Minzdrav of Russia 630091, Novosibirsk, Krasny av., 52
2Novosibirsk State Medical University of Minzdrav of Russia 630091, Novosibirsk, Krasny av., 52
3 Institute of Internal and Priventive Medicine of SB RAMS, 630089, Novosibirsk, Boris Bogatkov str., 175/1
4Novosibirsk State Medical University of Minzdrav of Russia 630091, Novosibirsk, Krasny av., 52
5Novosibirsk State Medical University of Miszdrav of Russia 630091, Novosibirsk, Krasny av., 52
6Novosibirsk State Medical University Minzdrava Russia 630009, Novosibirsk, Krasnyi av., 52
7Institute of Internal Medicine SB RAMS 630089, Novosibirsk, Boris Bogatkov str., 175/1
8Novosibirsk State Medical University Minzdrava Russia 630091, Novosibirsk, Krasniy av., 52
Abstract
Data showing the prognostic value of rs1625895 polymorphism in the TP53 gene in hematological malignancies were obtained previously. This data are consistent with the results of studies of the solid tumors. The objective of this study was to clarify the association between rs1625895 and the efficiency of R-CHOP therapy in DLBCL patients. Material and methods. 106 DLBCL patients diagnosed in the 2004–2010 were enrolled into the study. All patients received 6–8 courses of R-CHOP therapy as a first-line treatment. Results and discussion. The prognostic value of rs1625895 in aggressive non-Hodgkin’s lymphoma was confirmed in the group of patients with diffuse large B-cell lymphoma. It is shown that the age is not independent predictor of survival in patients DLBCL (p > 0.05) regardless of gender. Index IPI elaborated before retuximab use retains its prognostic value in patients received immunochemotherapy (both for male p = 0.036 and female p = 0.018). However, the G/G genotype of rs1625895 polymorphism in the TP53 gene was shown to be associated with a high probability of R-CHOP therapy failure in DLBCL patients according to the probability of remission as well as 5-year overall (p = 0.005) and relapse-free (p = 0.003) survivals in female patients.
Key words
References1. Voropaeva E.N., Voevoda M.I., Pospelova T.I. et al. Molecular-genetic approach to predicting the effectiveness of aggressive non-Hodgkin's lymphomas therapy // Byulleten' Sibirskogo otdeleniya Rossiyskoy akademii meditsinskikh nauk. 2014. 34. (2). 39–43. (in Russian)
2. Voropaeva E.N., Voevoda M.I., Pospelova T.I., Maximov V.N. Intronic polymorphisms antioncogene TP53 in patients of older age group with indolent non-Hodgkin's malignant lymphomas entities // Successes of gerontology. 2013. 26. (2). P.258–262. (in Russian)
3. Coviello A.D., Haring R., Wellons M. et al. A genome-wide association meta-analysis of circulating sex hormone-binding globulin reveals multiple Loci implicated in sex steroid hormone regulation // PLoS Genet. 2012. 8. (7). e1002805.
4. De Feo E., Persiani R., La Greca A. et al. A case-control study on the effect of p53 and p73 polymorphisms on gastric cancer risk and progression // Mutat. Res. 2009. 675. (1-2). 60–65.
5. Kochethu G., Delgado J., Pepper C., Starczynski J. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia // Leuk. Res. 2006. 30. (9). 1113–1118.
6. Mavridou D., Gornall R., Campbell I.G. TP53 intron 6 polymorphism and the risk of ovarian and breast cancer // Br. J. Cancer. 1998. 77. (4). 676–678.
7. Mechanic L.E., Bowman E.D., Welsh J.A. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors // Cancer Epidemiol. Biomarkers Prev. 2007. 16. 214–222.
8. Pangilinan F., Geiler K., Dolle J. Construction of a high resolution linkage disequilibrium map to evaluate common genetic variation in TP53 and neural tube defect risk in an Irish population // Am J. Med. Genet. A. 2008. 146A. (20). 2617–2625.
9. Paola Gallì Р. A case-control study on the combined effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population // BMC Cancer 2009. 9. 137.
10. Pfreundschuh M., Muller C., Zeynalova S. et al. Suboptimal dosing of rituximab in male and female patients with DLBCL // Blood. 2014. 123. (5). 640–646.
11. Sribudiani Y., Metzger M., Osinga J. Variants in RET associated with Hirschsprung‘s disease affect binding of transcription factors and gene expression // Gastroenterology. 2011. 20. (2). 572–582.
12. Wu X., Zhao H., Amos C.I. et al. P53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity // J. Nat Cancer Inst. 2002. 94. 681–690.
About Authors (Correspondence):
Voropaeva E.N. – candidate of medical sciences, researcher of the laboratory of molecular-genetic methods of study of the therapeutic diseases, е-mail: vena.81@mail.ru
Pospelova T.I. – doctor of medical sciences,, professor, head of the chair for therapy, hematology and transfusiology, е-mail: postatgem@mail.ru
Voevoda M.I. – corresponding member of the RAS, doctor of medical sciences,, professor, director, е-mail: mvoevoda@ya.ru
Maksimov V.N. – doctor of medical sciences, professor, head of the laboratory of molecular-genetic methods of study of the therapeutic diseases, е-mail: medik11@mail.ru
Berezina O.V. – candidate of medical sciences, assistant professor of the chair for therapy, hematology and transfusiology, е-mail: ovberezina@mail.ru
Ovchinnikov V.S. – postgraduate student of the chair for therapy, hematology and transfusiology, е-mail: black_wizard@mail.ru
Shcherbakova L.V. – senior researcher of the laboratory of clinical population and preventive studies of therapeutic and endocrine diseases, е-mail: 9584792@mail.ru
Babaeva T.N. – postgraduate student of the chair for therapy, hematology and transfusiology, е-mail: babaeva_tatyana@inbox.ru
Full Text
